Opexa Therapeutics
From Wikipedia, the free encyclopedia
Opexa Therapeutics NASDAQ: OPXA, formerly known as PharmaFrontiers, is a biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T cell vaccination technologies.
Key products and research include:
- Tovaxin: A T cell therapeutic vaccine for multiple sclerosis
- Cardiac stem cell therapy
- Diabetes stem cell therapy
[edit] Location
Opexa Therapeutics is located in The Woodlands, Texas 30 miles (48 km) north of Houston, Texas. The company has a 10,200 sq ft (950 m2) facility on 3 acres (12,000 m2) in The Woodlands. This location provides space for pipeline development through R & D; a specialized Flow cytometry and Microscopy lab; support of clinical trials with GMP manufacturing Suites; Quality Systems management with Quality Control Laboratory, Regulatory Affairs, Quality Assurance; as well as administrative support space.
